Investment Rating - The report assigns a "Buy-A" investment rating with a 6-month target price of 15.78 CNY [5][6]. Core Insights - The company is expected to benefit from the launch of its new health-oriented product, VitaYoung, which features a "6-zero" formula, aligning with health consumption trends and potentially driving significant sales growth [1]. - A new generation manager has taken over, indicating a shift towards professional and youthful governance, alongside a revamped marketing strategy that leverages online media and celebrity endorsements to enhance brand visibility among younger consumers [2]. - The company is experiencing a reduction in the cost of bulk powder, leading to an increase in gross margin, which is projected to continue improving due to favorable raw milk prices [3]. - The company has a strong commitment to shareholder returns, planning to distribute approximately 194 million CNY in cash dividends, which represents 86.57% of the net profit for the year [4]. Financial Projections - Revenue growth is forecasted at 8.0%, 8.5%, and 9.0% for the years 2025 to 2027, with net profit growth expected at 7.5%, 15.5%, and 15.1% respectively, indicating strong growth potential [5][18]. - The company’s revenue for 2025 is projected to be 1,528 million CNY, with a gross margin of 41.7% [19][26]. - The company’s earnings per share (EPS) is expected to increase from 0.60 CNY in 2023 to 0.81 CNY by 2027 [19][26]. Business Structure and Product Lines - The company focuses on sweet milk beverage products, with a significant portion of revenue coming from its core dairy drink segment, which has shown consistent growth [10][12]. - The product mix includes a variety of beverages, with dairy drinks accounting for 95.69% of revenue, while new product lines like plant protein and vitamin water are being developed to meet diverse consumer needs [12][16]. - The company has established a strong distribution network, covering over 2,600 dealers nationwide, which supports its market presence [13].
李子园(605337):健康新品维他命水有望放量,分红慷慨高股息积极回报股东